RxDoctor Payments Data

Daisy Li

Family Medicine · Stockton, CANPI 1740770007

Payments from drug & device makers

$15,886in general payments, 2019–2025

Across 828 payments — averaging $19.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Amgen$2K
  • Gilead$1K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Vifor Pharma, Inc.$922
  • plus $8K from 39 others

What the payments were for

  • Food & beverage$15,62798%
  • Education$2592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,886 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$85,227
Medicare patients
212
Services billed
969

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin128$139,517
OzempicSemaglutide79$97,294
FarxigaDapagliflozin Propanediol85$95,303
EliquisApixaban97$70,121
XareltoRivaroxaban82$66,892
VemlidyTenofovir Alafenamide27$33,733
JanuviaSitagliptin Phosphate46$32,980
TradjentaLinagliptin32$27,122
LinzessLinaclotide24$20,547
VascepaIcosapent Ethyl33$16,580
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$13,221
EntrestoSacubitril/Valsartan15$11,889
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$10,198
Spiriva RespimatTiotropium Bromide17$9,719
Tresiba Flextouch U-200Insulin Degludec11$9,508

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat$647$176,357177 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$2,136$114,425117 claims
Novo NordiskOzempic$1,011$97,29479 claims
Johnson & JohnsonXarelto, Procrit$127$74,95295 claims
PfizerEliquis, Paxlovid$63$73,158127 claims
GileadVemlidy$1,193$33,73327 claims
AbbVieLinzess$337$20,54724 claims
GSKTrelegy Ellipta, Incruse Ellipta$157$15,77824 claims
NovartisEntresto$503$11,88915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Stockton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →